Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Doses First Patients in Phase III Cholangiocarcinoma Trial

publication date: May 25, 2021

Suzhou Innovent has dosed the first patients in a China Phase III trial of pemigatinib, a fibroblast growth factor receptor 1/2/3 inhibitor, in patients with cholangiocarcinoma. The clinical test is the China arm of a global Phase III trial that compares the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin as a first-line therapy for advanced cholangiocarcinma with a FGFR2 rearrangement. In 2018, Innovent acquired greater China rights to the candidate from Incyte as part of a $390 million, three-drug deal. More details....

Stock Symbols: (HK: 01801) (NSDQ: INCY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.